🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  2. GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  3. GEMCITABINE, PACLITAXEL, PACLITAXEL

    Fondazione Telethon ETS

    Pancreatic cancer with peritoneal metastases

    phase 2 small molecule active

    1 trial

  4. GEMZAR 200 mg, poudre pour solution pour perfusion, ACR-368

    Acrivon Therapeutics

    Endometrial cancer

    phase 2 small molecule active

    1 trial

  5. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  6. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  7. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  8. GEN3014

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 mab terminated

    1 trial

  9. GEN3014 DP, DARZALEX 1800 mg solution for injection

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  10. GGTA1 KO Thymokidney

    United Therapeutics Europe Ltd

    ESRD (End-Stage Renal Disease)

    phase 2 mab active

    1 trial

  11. GIOTRIF 40 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 20 mg film-coated tablets

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  12. GLUCOSE 5 % B.BRAUN, solution pour perfusion, ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  13. GLUT1 DS

    Ultragenyx UK Limited

    Glut1 Deficiency Syndrome

    phase 2 small molecule completed

    1 trial

  14. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  15. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  16. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  17. GS030-DP, GS030-DP, GS030-DP

    GenSight Biologics S.A.

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  18. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  19. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  20. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  22. Gazyvaro 1,000 mg concentrate for solution for infusion., OMNIPAQUE 300 mg I/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Idiopathic Nephrotic Syndrome

    phase 2 small molecule active

    1 trial

  23. Gecacitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    cGVHD

    phase 2 small molecule active

    1 trial

  24. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources